Mutations of the p53 tumor suppressor gene constitute one of the most frequent molecular changes in a wide variety of human cancers and mice deficient in p53 have recently attracted attention for their potential to identify chemical genotoxins. In this article, we review the data on the susceptibility of p53 nullizygote (-/-), heterozygote (+/ -), and wild type (+/+) mice to various carcinogens. Induction of esophageal and tongue squamous cell carcinomas (SCCs) by methyl-n-amylnitrosamine was shown to be increased in p53 (+/-) mice, in addition to the high sensitivity shown by p53 (-/-) littermates. N,N-dibutylnitrosamine (DBN) treatment also caused more tumor development in p53 (+/-) than wild-type mice, as with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in the urinary bladder. In addition, p53 (+/-) heterozygotes proved more sensitive than wild type littermates to the induction of stromal cell tumors like hemangiomas/hemangiosarcomas by N-bis(2-hydroxypropyl)nitrosamine (BHP) or lymphomas and fibrosarcomas with other carcinogens. Analysis of exons 5-8 of the p53 gene demonstrated mutations in approximately one half of the lesions. With N-methyl-N-nitrosourea, preneoplastic lesions of the stomach, pepsinogen altered pyloric glands (PAPG), and a gastric adenocarcinoma, were found after only 15 weeks in p53 (-/-) mice, although there was no significant difference in the incidence of gastric tumors between p53 (+/+) and (+/-) mice in the longer-term. Regarding colon carcinogenicity, adenocarcinomas were observed limited to 1, 2-dimethylhydrazine treated p53 (-/-) mice in the short term, but again, no significant difference was evident between the p53 (+/+) and (+/-) cases at the end of the study. Furthermore, diethylnitrosamine or aminophenylnorharman treated p53 (+/-) mice did not demonstrate elevated susceptibility to tumors in the liver. With BHP, which induces tumors in multiple organs, p53 (+/-) mice were not more statistically sensitive with regard to lung tumor development than p53 (+/+). Of the malignant tumors examined in p53 (+/+) and (+/-) mice, as many as 10% demonstrated mutations in the p53 gene. These results suggest that p53 may not be a direct target for mouse adenomas/adenocarcinomas, but rather plays an important role as a gatekeeper in their genesis. In contrast p53 itself is frequently mutated in squamous, urothelial, or stromal tumors with a clear order of susceptibility: p53 (-/-) > p53 (+/-) > p53 (+/+) mice. p53 (-/-) mice are versatile animals for carcinogenicity testing, despite their disadvantage of a high background of spontaneous tumor development, and tissue dependence must be taken into account when exposing p53 (+/-) mice to chemical carcinogens. (J Toxicol Pathol 2005; 18: 121-134) 
Introduction
Mutations of the p53 gene constitute one of the most frequent molecular changes been in a wide variety of human cancers 1 . In addition to somatic mutations in sporadic cancers, germline mutations in the p53 gene are associated with the Li-Fraumeni syndrome, a familial autosomal dominant disease characterized by a predisposition to development of a variety of tumors 2 . As an animal model for this disorder, mice deficient in p53 alleles have been established [3] [4] [5] [6] . These animals show normal development, but homozygote knockouts (-/-) show extreme sensitivity to chemical carcinogens, almost irrespective of the organ 3 . However, the frequent spontaneous development of tumors in p53 knockout mice, including thymic lymphomas and sarcomas at young adult age, hinders their application for risk assessment purposes. p53 (+/-) mice, on the other hand, have only a low incidence of background spontaneous tumors until late in life 7, 8 and thus have attracted interest as experimental animals in tests for the carcinogenic potential of chemicals. The same mouse model has also been widely utilized for functional analysis of the p53 gene in carcinogenesis studies. There have been several reports that p53 (+/-) mice are highly sensitive to genotoxic carcinogens, such as N-butyl-N- (4-hydroxybutyl) nitrosamine (BBN) targeting the urinary bladder 9 , N-ethyl-N-nitrosourea (ENU) inducing uterine endometrial stromal sarcomas 10 , N,Ndibutylnitrosamine (DBN) causing esophagus and urinary bladder tumors 11 , methyl-n-amylnitrosamine (MNAN) active in the esophagus 12 and tongue 13 and urethane inducing vascular tumors 14 . However, p53 (+/-) mice have not been shown to have increased susceptibility to induction of hepatocellular tumors by diethylnitrosamine (DEN) 15 or breast tumors by 7,12-dimethyl[a]benzanthracene (DMBA) 16 . We have also shown only a minimal increment of sensitivity in p53 (+/-) mice to stomach tumors induced by N-methyl-N-nitrosourea (MNU) 17 , colon tumors after treatment with 1,2-dimethylhydrazine (DMH) 18 , and liver t u m o r s i n d u c e d w i t h a h e t e r o c y c l i c a m i n e , aminophenylnorharman (APNH) 19 . Furthermore, utilization of N-bis (2-hydroxypropyl) nitrosamine (BHP) for the induction of tumors in multiple organs, pointed to tissue specificity regarding susceptibility (Hirata et al., manuscript submitted) . In the present report, we review our data and discuss the mechanisms of the sensitivity of p53 knockout mice.
p53 as a Tumor Suppressor

Discovery of the p53
p53 is a tumor suppressor gene which is frequently altered in human malignancies 20 . Located on the short arm o f h u m a n c h r o m o s o m e 1 7 p 1 3 2 1 , w h e r e l o s s o f heterozygosity (LOH) is frequently observed in human cancers 22 , the gene yields a 2.8 kb mRNA transcript and encodes a 53 kD nuclear phosphoprotein composed of 393 amino acids 23 . The p53 protein was initially identified in SV40-transformed cells, where it was thought to be a transformation-specific protein or tumor antigen 2 4 . Transfection assays in NIH3T3 fibroblast cells initially suggested p53 to be an oncogene 25 , but subsequently it was demonstrated that only mutant forms of p53 possess the capacity to immortalize cells and the wild-type protein actually suppresses transformation 26 . Furthermore, a tumor suppressor role was suggested by the fact that LOH and point mutations in the remaining allele were frequently identified in colorectal 2 7 and lung 2 8 cancers. There is now overwhelming evidence that the normal function of p53 is in fact that of a tumor suppressor 29 .
Responses of p53 to DNA damaging agents
Damage to DNA induces several cellular responses that enable the cell either to eliminate or cope with the damage or to activate a programmed cell death process, so that potentially catastrophic mutations are not passed on to the next generation. There are many DNA damaging agents, including ionizing irradiation 30 , genotoxic chemical carcinogens 31 , and oxidative radicals 32 , which can cause genotoxic insult, including DNA strand breaks, and stimulate activation of checkpoint proteins. The DNA damage checkpoints employ damage sensor proteins, such as ataxia telangiectasia mutated (ATM), ATM-and Rad3-related (ATR), the Rad17-replication factor C (Rad17-RFC) complex, and the toroidal Rad9-Rad1-Hus1 checkpoint complex (9-1-1 complex), to detect DNA damage and to initiate signal transduction cascades involving checkpoint kinase (Chk) 1 and Chk2 Ser/Thr kinases and Cdc25 phosphatases. The signal transducers activate p53 and inactivate cyclin-dependent kinases to inhibit cell cycle progression 33 . The ATM gene, when mutated in the genetic instability syndrome ataxia telangiectasia, is linked to increased cancer risk. ATM and its related kinase, ATR, phosphorylate a number of down stream proteins, including p53, to effect stabilization 34 . Then p53 in turn plays a critical role in maintaining genome integrity by activating a biochemical chain reaction that leads to cell cycle checkpoint activation from G1 to S (the G1/S checkpoint) 35 or from G2 to mitosis (the G2/M checkpoint) 36 . In the G1/S checkpoint case, cyclin E-Cyclin-dependent kinase 2 (Cdk2) is inactivated by a p53-inducible Cdk inhibitor, p21 CIP1/WAF1 37 . The G2/M checkpoint involves inhibition of Cdc2, the cyclin-dependent kinase required to enter mitosis. Cdc2 is inhibited simultaneously by three transcriptional targets of p53, Gadd45, p21, and 14-3-3σ. Binding of Cdc2 to Cyclin B1 is required for its activity, and repression of the cyclin B1 gene by p53 also contributes to blocking entry into mitosis 36 . Cdc25A phosphatase 38 and Cdk2 kinase 39 appear central in the transient intra-S-phase response for repair of DNA damage during DNA replication (the intra-S checkpoint).
Cells try to repair their DNA during checkpoint delay. However, if the repair processes fail, p53 stimulates multiple apoptotic mechanisms including both nuclear and mitochondrial pathways 40 . p53 protein can directly induce permeabilization of the outer mitochondrial membrane by forming complexes with the protective BclXL and Bcl2 proteins, resulting in cytochrome c release with binding to BclXL via its DNA binding domain, in the intrinsic pathway 41 . p53 also functions to activate the pro-apoptotic proteins BAX and BAK on the mitochondrial membranes through direct physical interaction 42 . Besides these mitochondrial pathways, p53 also induces the expression of proteins in extrinsic death-receptor pathways mediated by elements such as FAS and DR5/KILLER 43 . p53 induces Fas mRNA expression by binding to its promoter region. DR5 is also induced by p53 in response to DNA damage and in turn promotes cell death through caspase-8 44 . p53 stimulates expression of caspase-6 45 , which cleaves the nuclear envelope protein lamin A and several transcription factors 46 . The pro-apoptotic Bid connects activation of the extrinsic death receptor pathway to activation of the mitochondrial disruption processes associated with the intrinsic pathway. p53 therefore appears to promote the convergence of intrinsic and extrinsic pathways through Bid regulation 47 . 3 were backcrossed to C57BL/6J females to obtain N4 mice, which are maintained at the Animal Facility of Aichi Cancer Center Research Institute in a collaborative effort. The genetic background of our p53 knockout mouse is estimated to be more than 15/16 C57BL/6J and less than 1/ 16 129Sv. To analyze susceptibility, three different experimental periods were basically selected to examine (1) preneoplastic lesions in the short term, (2) differences in tumor yield between p53 heterozygous (+/-) and nullizygous (-/-) mice using small amounts of carcinogens, in the midterm, usually 15 weeks, and (3) lastly to show differences between p53 wild-type (+/+) and heterozygous (+/-) mice using standard carcinogen doses in longer term experiments for up to one year.
Development of p53 Knockout Mice
Heterozygous p53 Knockout Mice are Susceptible to Carcinogens
Esophageal carcinogenesis
To analyze esophageal squamous cell carcinogenesis 12 , drinking water containing 5 or 15 ppm of MNAN was provided to p53 (+/+), (+/-), and (-/-) mice for 8 weeks. The animals were then maintained without further treatment for an additional 7 or 17 weeks. Sacrifices of mice of the three genotypes took place at week 15 and at week 25 p53 (+/+) and (+/-) mice were sacrificed. Three groups of p53 ( + / + ) , ( + / -) , o r ( -/ -) c o n t r o l a n i m a l s r e c e i v e d unsupplemented drinking water. Administration of MNAN induced a 100% incidence of esophageal diffuse hyperplasia in p53 (-/-), (+/-), and (+/+) mice, often accompanied by subepithelial inflammatory infiltration. In the mice treated with 5 ppm MNAN, the incidence of squamous cell carcinomas (SCCs) was significantly higher (P<0.001) in p53 (-/-) than in p53 (+/-) and (+/+) mice at 15 weeks after starting treatment. At 25 weeks, the SCC incidence in p53 (+/-) was significantly greater (P<0.05) than in p53 (+/+) mice. Only one SCC developed, in a p53 (+/+) mouse at 25 weeks. The total number of tumors per mouse (mean ± SD) was also higher in the p53 (-/-) (4.8 ± 1.4 /mouse) than in the p53 (+/-) (1.5 ± 1.2) and p53 (+/+) (0.8 ± 0.9) groups at 15 weeks (P<0.001) and it was greater in p53 (+/-) (4.4 ± 2.6) than in p53 (+/+) (2.7 ± 1.5) mice at 25 weeks (P<0.05). In the mice receiving 15 ppm MNAN, there was a trend of higher SCC incidence in p53 (+/-) as compared to p53 (+/+) mice at 15 and 25 weeks. PCR-SSCP and sequencing analyses for exons 5-8 of the p53 gene were performed and mutations were identified in 6 out of 12 esophageal SCCs (50%) and 14 out of 23 SCCs (61%) in p53 (+/+) and p53 (+/ -) mice, respectively. Only one of 19 papillomas examined had a mutation. LA-PCR-amplified DNAs from frozen samples exhibited missense mutations not in the mutant but rather in the wild type allele, indicating loss of functional p53 protein ( Fig. 1 and Table 1 ).
Nishikawa et al. 11 administered 0.025% or 0.05% N,Ndibutylnitrosamine (DBN) in drinking water to p53 (+/-) mice as well as to the wild type controls for 20 weeks. This chemical targets different organs, including the esophagus in which papillary hyperplasia, papillomas, and SCCs were induced. The incidence of papilloma was significantly higher in p53 (+/-) than in p53 (+/+) mice (P<0.05) in the 0.05% dose group. Furthermore, p53 (+/-) mice had more SCCs than their wild type counterparts with both doses (P<0.05). Analysis of the p53 gene status in esophageal mucosa in DBN treated animals revealed mutations at high frequencies in both p53 (+/+) and p53 (+/-) mice without any differences between the p53 genotypes ( Table 1) .
Tongue carcinogenesis
MNAN induces papillomas and SCCs of the tongue as well as the esophagus 1 3 . At week 15, although no microscopic changes were observed in either p53 (+/+) or (+/ -) mice, SCCs were found in 5/12 (41.7%) p53 (-/-) mice, the incidence being significant (P<0.05 and P<0.01 vs. p53 (+/+) and p53 (+/-), respectively). Additionally, one of five p53 (-/-) mice exhibited SCC development and another had a papilloma. At week 25, carcinoma in situ (CIS) was observed in one each of the p53 (+/+) and (+/-) mice, together with a papilloma in the latter animal. The rare occurrence of tongue neoplasms in wild type and heterozygous p53 knockout mice in that study might have been a reflection of murine resistance to tongue carcinogenesis by MNAN as compared to 4-nitroquinoline-1-oxide (4NQO) 50 . p53 mutations were identified in the CIS in the p53 (+/+) mouse, and in the papilloma of the p53 (+/-) mouse (Table 1) .
Carcinogenesis in the urinary bladder
Ozaki et al. 9 used BBN to induce tumors in the urinary bladder. p53 (+/+) and p53 (+/-) mice were administered 0.004, 0.0075, or 0.025% BBN in drinking water for 20 weeks, resulting in development of dysplasia, transitional cell carcinoma (TCCs or urothelial carcinomas) and SCCs. In the 0.0075% treated groups, the incidence of dysplasia was significantly higher in p53 (+/-) than in wild type (P<0.05) mice. The frequency of p53 mutations in dysplasia and TCC was about 20% for both genotypes. In contrast, 50% (4/8) of SCCs had mutations in p53 (+/-) mice. The p53 (+/+) mice did not demonstrate any SCCs (Table 1 ). In the same experiment, hemangiomas and hemangiosarcomas were also observed in the urinary bladder. The incidence of these stromal tumors in p53 (+/-) was significantly higher than in their wild type counterparts (P<0.005) ( Table 1) . In another study, DBN induced neoplastic lesions in the urinary bladder as well as in the esophagus 11 and the incidence of TCCs was significantly higher in p53 (+/-) than in p53 (+/+) mice, with both 0.025% and 0.05% doses (P<0.05). Stromal tumors were also observed, p53 (+/-) animals demonstrating more fibrosarcomas in the 0.025% group than p53 (+/+) mice (P<0.05) ( Table 1) .
Development of vascular tumors in the liver
For simultaneous tumor induction in various organs, BHP was chosen to induce liver vascular tumors as well as lung tumors (Hirata et al., manuscript submitted) . In a midterm experiment, male p53 (+/+), (+/-), and (-/-) mice were given drinking water containing 20 ppm BHP, or 200 ppm for homozygotes and the wild type. Liver vascular tumors were found and histologically diagnosed as hemangiomas and hemangiosarcomas; some of them were confirmed to be immunohistochemically positive for von Willebrand factor. In the 15-week experiment group treated with 20 ppm BHP, vascular tumors were found in only p53 (-/-) mice, at incidences showing statistical significance compared with p53 (+/+) and (+/-) mice (P <0.005 and P <0.05, respectively). Hepatic vascular tumors also developed in all surviving p53 (+/-) mice, whereas p53 (+/+) tumor yields were significantly lower with 200 ppm (hemangiomas P<0.001; hemangiosarcomas P<0.001). For longer term observation, male p53 (+/+) and (+/-) mice were given 20 ppm BHP for 40 weeks. Incidences of liver vascular tumors in BHP-treated p53 (+/-) mice were significantly higher than in the wild type counterparts (hemangioma P<0.01; h e m a n g i o s a r c o m a P < 0 . 0 0 0 1 ) .
T w e n t y l i v e r hemangiosarcomas were subjected to microdissection, PCR-SSCP, and sequencing analysis of p53 exons 5-8 and p53 mutations were identified in 12 of 20 (60.0%) lesions. The frequency was significantly higher than that in lung tumors (described below) in which the mutation rate was only as low as 10%. Mutations in all five hemangiosarcomas (5/5, 100%) were found to be located in the wild-type allele of p53 (+/-) mice, indicating complete loss of functional p53 protein ( Fig. 2A and Table 1 ).
Target cells decide sensitivity of p53 (+/-) mice
Not only nullizygous but also heterozygous p53 knockout mice are more susceptible to esophageal tumorigenesis induced by MNAN 12 , than their wild-type counterparts, as indicated by an increased incidence of SCCs. In addition, accelerated tumor development with chemical exposure in p53 (+/-) mice has been reported with regard to lymphomas 51 , mesotheliomas 52 , skin tumors 53 , vascular tumors 14 , urinary bladder tumors 53 , and lung tumors 54 (representative photos of a sarcoma and a lymphoma are shown in Fig. 2, B and C) . Transitional cell carcinoma development in the urinary bladder was also found to be enhanced in BBN treated p53 (+/-) mice as compared with the C57BL/6 parental strain 9 . The data thus suggest that squamous cell and transitional cell epithelia may be more influenced by decrease of p53 protein amount or that the p53 gene of the wild type allele could be a direct target in these tissues. In contrast, spontaneous sarcomas 55 and skin SCC induced with dimethylbenzanthracene plus 12-O-tetradecanoyl-phorbol-13-acetate (TPA) 56 need only partial reduction of p53 protein amount in (+/-) mice compared with (+/+) mice for cancer promotion and progression. In the latter case, the progression rate was also greater in (+/-) than (+/+) mice and was associated with loss of the remaining wild type allele. Ozaki et al. 9 reported a high susceptibility of p53 (+/-) mice to BBN urinary bladder carcinogenesis without frequent p53 gene mutations. Therefore, a lack of increased susceptibility may reflect organ/tissue specificity for the levels of p53 protein required for tumorigenesis, in addition to involvement of p53 gene alterations.
Heterozygous p53 Knockout Mice are not Sufficiently Susceptible to Carcinogens for Effective Short-Term Testing
Carcinogenesis in the stomach
An experiment was conducted to determine the sensitivity to induction of preneoplastic lesions, pepsinogen altered pyloric glands (PAPGs), within 5 weeks, and to clarify any differences in tumor yields between p53 (+/-) and (-/-) mice administered 30 ppm MNU for 15 weeks 17 . A longer study was also conducted to show the variation in responses between p53 (+/+) and (+/-) mice administered 30 or 120 ppm MNU. Serial sections including pyloric glands were stained with anti-pepsinogen 1 (Pg 1) antibody 57 and were evaluated for PAPG. PAPG were stained weakly or negative for Pg 1, and it was established that they are putative precancerous lesions in the mouse 57 , and also in the rat 58, 59 . In the 5-week experiment, histological sections showed slightly irregular glands and weak hyperplasia or atrophy, especially in the p53 (-/-) mice. Pg 1 staining revealed PAPG even in normal looking mucosa in MNUtreated p53 (-/-) mice, in contrast to the control mice in which Pg 1 was consistently present in pyloric gland cells. The frequency of PAPGs was 22.6 ± 14.9% (mean ± SD) in MNU-treated p53 (-/-) mice, significantly elevated (P<0.001) compared with the values for MNU-treated p53 (+/+) and p53 (+/-) mice (1.8 ± 1.0 and 1.7 ± 0.8%, respectively) and the control groups (1.0 ± 0.4, 1.0 ± 0.3, and 1.2 ± 0.6 % in p53 (+/+), (+/-), and (-/-) mice, respectively). We were thus convinced that nullizygous (-/-) p53 knockout mice are much more susceptible to stomach carcinogenesis induced with MNU than their heterozygous or wild type counterparts. In the 15-week experiment, MNU strongly affected p53 (-/-) mice, resulting in high mortality compared to the other two groups, with development of lymphomas or sarcomas 3, 7, 8 . Stomach lesions including hyperplasia, adenomas, and an adenocarcinoma were found only in MNU-treated groups. Adenomas were found only in p53 (+/-) and (-/-) mice, along with a single well differentiated adenocarcinoma in a homozygote. The trend of these lesions was revealed to be significantly shifted toward malignancy in p53 (-/-) mice compared with p53 (+/ +) and (+/-) mice. In the long term experiment, there were no significant differences in the incidences of glandular stomach lesions at week 40 between p53 (+/+) and (+/-) mice. Fifty-one animals were observed to have adenocarcinomas, which included 44 well differentiated, 4 poorly differentiated, and 3 signet-ring cell carcinomas. The results for PAPG coincided well with the fact that tumors in p53 (-/-) mice developed within 15 weeks. A total of 68 gastric tumors were subjected to PCR-SSCP analysis. Although simultaneously developing lymphomas and sarcomas in MNU-treated groups showed mutations in the wild type allele of the p53 gene, none of those gastric tumors proved to have any mutations 17 (Fig. 3 , A-C and Table 2 ).
Colon carcinogenesis
p53 (+/+), (+/-), and (-/-) mice were treated with subcutaneous injections of DMH at a dose of 20 mg/kg body weight, once a week for 5 or 15/16 weeks in short-and midterm experiments, then sacrificed two weeks after the final injection 18 . Colonic lesions were classified into focal atypias, adenomas, and adenocarcinomas. In the DMH-treated p53 (-/-) mice, three mice developed adenomas (3/14 = 21.4%) and the mean number of focal atypia per unit length of colon was 0.059 ± 0.13 /cm in contrast to a complete lack of them in (+/ +) and (+/-) animals in the short-term experiment. In the mid-term experiment, focal atypias and adenomas appeared in DMH-treated p53 (+/+) and p53 (+/-) mice, along with carcinomas in the p53 (-/-) case. The incidences of tumors of DMH-treated p53 (-/-) mice were significantly higher than values for the other DMH-treated genotypes and control groups. In the long-term experiment (30 weeks), there were no significant differences between values for tumors in p53 (+/+) and (+/-) mice (P>0.999 for adenomas and P=0.315 for carcinomas). A total of 56 colonic proliferative lesions were subjected to PCR-SSCP analysis of p53 exons 5-8. PCR products in most cases appeared to migrate at the same speed as normal controls, but bands in four cases for exons 7 and 8 were shifted. Mutations were observed in one carcinoma in a p53 (+/-) mouse and one each in a focal atypia, an adenoma and a carcinoma in three p53 (+/+) mice. No LOH was found in any tumor or focal atypia in p53 (+/-) mice (Fig. 3, D and E and Table 2 ).
Liver carcinogenesis
APNH, a novel heterocyclic amine, was synthesized by Totsuka et al. 60 and mixed into CA-1 (Clea Japan, Tokyo, Japan) diet at 3, 10, and 30 ppm for ad libitum administration to p53 (+/+), (+/-), and (-/-) male mice for 15 weeks, and to both sexes of p53 (+/+) and (+/-) mice for 40 weeks 19 . Liver lesions were diagnosed as oval cell hyperplasia, foci, adenoma, and adenocarcinoma. In the 15-week experiment, preneoplastic foci were limited to p53 (-/-) mice treated with 10 ppm or 30 ppm of APNH, albeit without statistical significance as compared to the other genotypes. Various hepatic lesions including hepatocellular adenomas and hepatocellular carcinomas (HCCs) developed by week 40, especially in females. Altered cell foci were observed at all dose levels in p53 (+/-) males and females, 30 ppm p53 (+/ +) males, and 10 and 30 ppm dosed p53 (+/+) females. Significant induction of adenomas and carcinomas was found in p53 (+/-) and p53 (+/+) female mice receiving 30 ppm of APNH, relative to controls. However, there were no significant differences between the p53 (+/+) and p53 (+/-) cases. Analysis of exons 5-8 of the p53 gene was performed on 13 and 10 HCC samples from p53 (+/-) and p53 (+/+) mice, respectively, and 2 hepatocellular adenoma samples each from p53 (+/-) and (+/+) mice. No evidence of p53 gene mutations, however, was obtained (Table 2) .
Lung carcinogenesis
W e h a v e r e c e n t l y p e r f o r m e d a m u l t i o r g a n carcinogenesis study to assess the mechanisms that may determine the susceptibility of p53 knockout mice to tumorigenesis (Hirata et al., manuscript submitted) . The three genotypes were given drinking water containing 20 or 200 ppm BHP for 15 weeks in a mid-term experiment as described above under "Development of vascular tumors in the liver". Lung adenocarcinomas were observed after a period as short as 15 weeks and the incidence was significantly higher in p53 (-/-) than the other genotypes. p53 (+/+) and (+/-) mice were found to have only adenomas at 15 weeks. In contrast, there were no statistically significant differences in the incidences of lung lesions between p53 (+/+) and (+/-) mice. A longer-term observation of male and female p53 (+/+) and (+/-) mice given 20 ppm BHP water for 40 weeks also did not reveal any statistically significant differences in specific lung lesions, although the incidences of lung tumors in heterozygotes of both sexes tended to be higher. In addition, bronchial tumors were found in the long-term observation and again the incidences were higher in p53 (+/-) than in p53 (+/+) mice, but without statistical significance. Twenty lung adenomas and 17 adenocarcinomas were subjected to analysis of the p53 gene and mutations were identified in two (10.0%) and two (11.8%), respectively. The frequency of p53 mutations in lung tumors was significantly lower than in hemangiosarcomas (P<0.01) (Fig. 3 , F and G and Table  2 ).
Intraperitoneal injection of ENU has also been used to induce tumors in multiple organs by Mitsumori et al. 10 . Regarding lung tumors, the incidence of adenomas was significantly higher in p53 (+/-) than that in p53 (+/+) mice (P<0.05). Furthermore, the incidence of atypical endometrial hyperplasia was also higher in the heterozygotes (P<0.05). The p53 deficient mice used in that study had been established by Tsukada et al. 4 and backcrossed with female CBA mice and this might explain the discrepancy with our data (Table 1) .
p53 (-/-) Mice are most sensitive
Since stomach cancer developed in wild type mice in a previous study 57 , loss of p53 is not indispensable for stomach carcinogenesis. The results of PCR-SSCP analysis reported above support the idea of no essential role for p53 by revealing no mutations in exons 5-8 of the p53 gene in 68 stomach tumors, analyzed in BALB/c mice as reported by Furihata et al. 61 . However, complete loss of wild type p53 expression greatly enhanced stomach carcinogenesis. Thus the p53 gene might not be a direct target of MNU but the p53 protein might act as a gatekeeper 62, 63 for initiation of neoplasia, as indicated by the PAPG data, and for tumor promotion and progression, as reflected in the more advanced stomach lesion development in p53 (-/-) mice. Regarding colon carcinogenesis, the C57BL/6J strain, the background to the p53-deficient mice reviewed here used in the study mentioned above 3 , is moderately resistant to DMH, with 43-48% tumor incidences reported 64, 65 . However, colon carcinomas were already observed in 70% of p53 (-/-) mice after only 16 weeks of DMH treatment, with considerable reduction in the latency. The high susceptibility of p53 (-/-) to DMH-induction of colorectal carcinogenesis indicates that loss of p53 function has an accelerating effect. In vitro experiments have shown that non-tumorigenic colonic epithelial cells from p53 (-/-) mice acquire tumorigenic potential upon ectopic expression of an activated Ki-ras gene 66 . Therefore, complete lack of p53 may facilitate tumorigenesis on activation of oncogenes or inactivation of other tumor suppressor genes, and degrees of gene alteration may be reflected in grades of malignancy. In particular, activating mutations in the β-catenin gene are thought to be responsible for the excess β-catenin signaling featured in the majority of carcinogen-induced colonic lesions 67 , including small foci 68 . Mammary carcinogenesis induced by DMBA 16 and hepatocarcinogenesis initiated with the genotoxic carcinogens dimethylnitrosamine (DMN), 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP), 6-nitrochrysene (6-NC) 69 , 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) 70 , DEN 15 , and other chemicals 71 including APNH, a novel heterocyclic amine 19 , may reflect organ/tissue specificity in the threshold for the p53 gene product. While the mechanism may involve an additional hit to inactivate the second normal allele, Venkatachalam et al. 55 have proposed that reduction of the p53 gene products may be sufficient to promote tumorigenesis.
Conclusions
Mutations in the p53 gene commonly occur at hot spots in human cancers 1 , but the mutation database for laboratory animals is limited. Our previous study revealed no mutations in 68 MNU-induced gastric tumors using PCR-SSCP analysis in p53 deficient mice 17 , while the mutation rate observed for the p53 gene was 3 in 46 (6.5%) colonic tumors in p53 (+/-) and (+/+) mice, much lower than that observed for human colon cancers. Moreover, allelic loss of tumors in heterozygous mice was not detected in that study, while LOH is frequent (75%) in colon carcinomas in humans. In humans, inactivation of p53 is most often due to a missense mutation combined with loss of the other allele 72 . In colon adenocarcinomas of rats treated with DMH or azoxymethane, p53 gene alteration was only rarely detected w i t h P C R -S S C P a n a l y s i s i n a n e a r l i e r s e r i e s o f experiments 73 . Similarly, Okamoto et al. 74, 75 conducted a PCR-SSCP analysis of exons 5-8 in p53 genes in DMHinduced colonic neoplasms and revealed 33 mutations in 22 of 182 (12.1%) colon tumors (including multiple mutations), but again allelic loss was detected in only 2 of 163 lesions (1.2%). Since p53 (+/-) mice have one inactive allele, they might have been predicted to be more susceptible to carcinogenesis compared with their wild type counterparts. Analysis of the p53 gene demonstrated no mutations in the liver tumors developing in either p53 (+/+) or p53 (+/-) mice, consistent with the lack of structural aberrations in the p53 gene in carcinogen-induced liver tumors in C57BL/6J strain mice 76 . In contrast, PCR-SSCP analysis revealed a high frequency of missense mutations in p53 with evidence of loss of functional p53 protein in esophageal malignancies. Taken together, these results support the hypothesis that mutational inactivation of the retained wild-type allele or loss of p53 heterozygosity, with consequent loss of p53 function, eventually results in development of neoplasias as occurs in human Li-Fraumeni syndrome 77 . Our results point to a high frequency of p53 mutations in esophageal malignancies, the most common being missense, as reported for human cancer 78 . In contrast to the frequent p53 mutations in SCCs, even in small carcinomas, only one mutation was detected in 19 papillomas analyzed. Similar findings have been reported in murine skin tumors induced with benzo[a]pyrene in which the majority of p53 mutations were identified in SCCs; they were rare in papillomas 79 . Moreover, abnormal p53 protein is only infrequently identified in human esophageal squamous cell papillomas 80 while dysplastic lesions exhibit p53 mutations 81, 82 . Regarding the location of p53 mutations, they were randomly distributed through exons 5 to 8, with more than one mutation detected at codons 164 (8%, 2/25), 219 (4/25, 16%), 232 (2/25, 8%) and 250 (4/25, 16%). Approximately half of the mutations observed in our study were G:C to A:T transitions at non-CpG sites. Retrospective analyses of p53 gene mutations in human esophageal cancers have also shown a predominance of G:C to A:T transitions 83, 84 , i n d i c a t i n g t h a t t h e M N A N -i n d u c e d e s o p h a g e a l carcinogenesis model mimics the human disease. In dimethylbenzanthracene / 12-O-tetradecanoyl-phorbol-13-acetate induced skin carcinogenesis in p53 deficient mice, LOH of the p53 gene in (+/-) mice enhanced malignant progression 56 . From these results, p53 alteration may be organ-specific (Fig. 4) .
In summary, our studies indicate that p53 (-/-) mice may be universally susceptible to carcinogens, whereas sensitivity in p53 (+/-) mice is organ-specific and dramatically increased by involvement of p53 gene alterations in the carcinogenic process, in addition to mechanisms related to haploinsufficiency. Though p53 knockout mice are powerful tools for identification of carcinogens, organ/tissue and carcinogen specific susceptibility must be taken into consideration for appropriate evaluation.
